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Proteoglycans (PGs) are a family of molecules that
undergo extensive post-translational modifications that
include addition of glycosaminoglycan (GAG) chains as
well as N- and O-linked oligosaccharides to the protein
core. PG composition and structure have been reported
to alter with age. To test whether the post-translational
modifications to PGs can serve as in vitro surrogate end
point markers for chronological age, the extent of GAG
modifications was determined for PGs derived from nor-
mal human bone cells of 14 donors (age range, fetal to 60
years). Isolated cells were steady state radiolabeled with
35SO4
2 and [3H]GlcN. For biglycan and decorin, idur-
onate content was linearly correlated with age (in-
creased 1.5 between fetal and age 60 years). For the
syndecan-like heparan sulfate PG, the N-sulfation of
post-natal cells increased over 3.5-fold until reaching a
plateau during the 4th decade of life. The amount of
O-linked oligosaccharides was also found to decrease as
a function of increasing normal donor age, whereas the
specific activity of the metabolic precursor pool remained
constant regardless of donor age. These age-related
changes in post-translational modifications were then
used to demonstrate that osteoblasts derived from pa-
tients with osteogenesis imperfecta did not exhibit facets
of a pre-mature aging, but rather were arrested in a fetal-
like phenotypic state. A growth matrix rich in throm-
bospondin altered PG metabolism in osteoblastic cells,
resulting in the production and secretion of the fetal-like
(rich in O-linked oligosaccharides) forms of decorin and
biglycan. This effect was qualitatively different from the
effect of transforming growth factor-, which predomi-
nantly altered GAGs rather than O-linked oligosaccha-
rides. No other Arg-Gly-Asp protein (fibronectin,
vitronectin, type I collagen, osteopontin, and bone sialo-
protein) showed any detectable effect on PG metabolism
in bone cells. These results indicate that a proper matrix
stoichiometry is critical for metabolism of PGs.
Osteogenesis imperfecta (OI)1 is a heritable disease of the
connective tissue characterized by bone fragility and skeletal
deformities. Short stature, blue sclerae, laxity of ligaments,
non-union of fractures, keloid and hyperplastic callus forma-
tion are among frequently encountered symptoms (1). The orig-
inal clinical classification of OI defined four types on the basis
of phenotypic severity (2, 3). The clinical heterogeneity was
reflected by a variety of mutations in the COL1A1 and COL1A2
genes that are thought to be the underlying cause of most cases
of OI (4). Recently, a new group of patients have been defined
in terms of clinical severity and by the exclusion of type I
collagen gene mutations (5, 6). The lack of a clear relationship
between collagen mutation and phenotype as well as the ab-
sence of type I collagen mutations in the recently defined
groups has suggested the involvement of other modifying
factors.
Proteoglycans (PGs) are a family of molecules that possess a
core protein to which one or more glycosaminoglycan (GAG)
chains are covalently attached (7). In addition, PG core pro-
teins may also possess N- and O-linked oligosaccharides. Hu-
man bone cells in culture produce a large versican-like PG, a
heparan sulfate syndecan-like PG, as well as biglycan (BGN)
and decorin (DCN) (8). Osteoblast cells derived from OI pa-
tients were found to have reduced levels of collagen, osteonec-
tin, large chondroitin sulfate PG, BGN, and DCN when com-
pared with levels found in age-matched control bone cell
cultures (9). The failure of OI osteoblast-like cells to parallel
the normal donor age-dependent expression pattern of matrix
genes was found to occur throughout long term culture (10).
Osteoblast-like cell strains derived from OI patients had sig-
nificantly reduced growth parameters (11). The reduction in
maximal cell growth rates and levels of extracellular matrix
components observed in OI-derived osteoblast-like cells, al-
though abnormally low compared with age-matched controls,
are equivalent to values observed in cells derived from elderly
donors 60 years of age (12). Thus, OI could be exhibiting
facets of normal aging and the observed phenotype of osteope-
nia and brittle bones would then share certain common fea-
tures with age-related osteoporosis.
The fine structure of PGs have been reported to change as a
function of donor age in other organ systems (13). The current
study was undertaken to determine whether post-translational
modifications to PGs can serve as surrogate biochemical mark-
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used to evaluate whether the expression pattern observed in
bone cells derived from OI patients were consistent with an
accelerated aging where the physiological age of the bone is
well advanced beyond chronological age. The biological signals
associated with these altered post-translational modifications
were investigated.
EXPERIMENTAL PROCEDURES
Reagents—Ultrapure guanidinium HCl, glycine, and Tris-HCl were
obtained from Invitrogen. Dulbecco’s modified essential medium
(DMEM) and heat-inactivated fetal bovine serum (FBS) were obtained
from BioFluids, Inc. (Rockville, MD). Formamide, barium nitrite, tissue
culture grade type IV collagenase, glutamine, penicillin, streptomycin,
ascorbate, and bovine serum albumin (BSA) were purchased from
Sigma. [35S]SO4
2 and [6-3H]GlcN were obtained from PerkinElmer Life
Sciences and Tran35S-label ([35S]methionine/cysteine) was purchased
from ICN, Inc. (Cosa Mesa, CA). Size exclusion chromatography resins
Toyopearl HW 40(S), 55(S), and 75(F) were purchased from TosoHaas,
Inc (Montgomerville, PA). Analytical HPLC SAX columns and Partisil
PAC 10 columns were obtained from Phenomenex Inc. (Torrance, CA).
Chondroitinase ABC (Proteus vulgaris) and ACII (Arthrobacter aurescens)
were purchased from Seikagaku America (Falmouth, MA). Throm-
bospondin was isolated from human platelets (14); bone sialoprotein was
isolated from a rat osteosarcoma variant, UMR-106-BSP (15); osteopontin
(also called uropontin), isolated from human urine, was a gift from Dr. J.
Hoyer, University of Pennsylvania (16). Serum-free conditioned medium
(SFCM) was obtained from normal, primary human trabecular bone cells
incubated in serum-free medium supplemented with 0.5% ITS (2.5
g/ml insulin/transferrin/selenium, 0.5 mg/ml BSA, and 0.5 g/ml linoleic
acid) for 24 h prior to collection. ITS, vitronectin, and fibronectin were
purchased from Collaborative Research, Inc. (Bedford, MA). Bovine colla-
gen type I was purchased from Worthington. TGF- was purchased from
R & D Systems, Inc. (Minneapolis, MN). Agarose was purchased from
FMC Bioproducts, Inc. (Rockland, ME).
Human Bone Cell Culture—Recruitment of subjects donating osteo-
blasts was in accordance with approved procedures of the Institutional
Review Board, The Johns Hopkins Bayview Medical Center. Normal
bone samples from 22 different donors were taken during surgery for
fracture non-union and grafting with benign bone tumors. In some
cases, samples were obtained during autopsy by sterile biopsy within
2–6 h of death. A diagnosis of OI was made based upon patient history
of fractures, family history, presence of blue sclerae, and radiographic
evidence of osteopenia. Bone was obtained from the following: 6 type I
OI patients who exhibited limited skeletal deformity and were 1 to 3
S.D. below normal age-matched height; 2 type II OI patients that died
shortly after birth from respiratory insufficiency; 6 type III OI patients
that presented with severe skeletal deformities and dwarfism; and 8
type IV OI patients that showed skeletal deformities as well as signif-
icantly short stature. The mean age and range as well as number of
fractures per year are give in Table I. The bone was cultured as de-
scribed previously (9, 17). Briefly, bone was stripped of adherent peri-
osteum, cut into small pieces, and treated with 250 units/ml type IV
collagenase in DMEM for 2 h. The collagenase-treated bone chips were
rinsed and then cultured in low calcium medium (0.2 mM CaCl2/DMEM)
containing 10% heat-inactivated FBS, 2 mM glutamine, 100 units/ml
penicillin, 100 g/ml streptomycin, and 50 g/ml ascorbate. After about
5–7 days, outgrowth of bone cells started from the bone chips and
confluency in 15-cm2 dishes was usually reached after 4–6 weeks. For
these studies, only first passage cells were used.
The first passage cells were seeded at a density of 20,000 cells per
cm2 in DMEM supplemented with 10% heat-inactivated FBS, gluta-
mine, penicillin/streptomycin, and ascorbate. After 48 h this was
changed to media from which the antibiotics had been omitted. After
24 h the cells were labeled with 50 Ci/ml of [35S]SO4
2 and 10 Ci/ml
[6-3H]GlcN in low sulfate-containing DMEM supplemented with 2%
dialyzed FBS, ascorbate, and glutamine for 24 h. For harvesting, the
cell layer was extracted at 4 °C in 0.05 M Tris buffer, pH 7.4, containing
4.0 M guanidine HCl, 0.5 M EDTA, and 2% Triton X-100 (extraction
buffer) overnight. The medium was diluted 1:1 with extraction buffer
and also incubated overnight. All labeling was done in triplicate. Cell
number was determined in parallel cultures in triplicate at the end of
the labeling period after trypsinization by use of a Coulter counter
(Beckman Instruments, Hialeah, FL) in order to assess the proliferative
capacity of osteoblasts.
Proteoglycan Isolation—Radiolabeled pools were desalted by chroma-
FIG. 1. Proteoglycan distribution in normal and OI osteoblasts. Osteoblasts derived from normal donors (A–F) or from patients with OI
(G–L) were steady-state radiolabeled with [35S]SO4
2. The levels of 35S-labeled PGs in the medium and cell layer pools produced by osteoblasts in
primary culture were determined as described under “Experimental Procedures.” For comparative purposes, the total (medium  cell layer) levels
normalized on a per 106 cell basis were graphed as a function of phenotype and donor age. HSPG, heparan sulfate syndecan-like PG; CSPG,
versican-like chondroitin sulfate PG.
TABLE I
Patient data
NL OI type I OI type II OI type III OI type IV
n 14 6 2 6 8
No. fractures/year 0–2 a 10–30 2–15
Mean age (years) 20 35 0.4 7 16
Range 0.25–60 8–60 0.25–0.45 2–13 3–45
a Both type II patients died shortly after birth from respiratory insufficiency.
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tography over a 1.0  25-cm column packed with TSK-GEL Toyopearl
HW 40(S) and equilibrated in 50% formamide, 40 mM KH2PO4, 0.1 M
KCl, and 0.5% Triton X-100 (18). After fractionation by charge density
on a Nucleogen DEAE 4000–7 column, PGs were further separated by
size distribution using a TSK-GEL ToyoPearl HW 75(F) column as
described (18).
Proteoglycan Analysis—GAG chains were liberated by alkaline boro-
hydride treatment (0.5 M NaBH4 in 0.4 N NaOH for 24 h at 25 °C) and
isolated by ToyoPearl TSK-GEL HW 40(S) chromatography (18). This
chromatographic step enabled the resolution of GAG chains from O-
linked oligosaccharides released by alkaline borohydride treatment,
thus enabling the determination of the relative incorporation of
[3H]GlcN/[3H]GalN into both GAG chains and O-linked oligosaccha-
rides. The size of the GAG chains was profiled by gel permeation
chromatography using a 1.0  30-cm ToyoPearl TSK-GEL HW 55(S)
column equilibrated in 4 M guanidine HCl (19).
Glycosaminoglycan Structural Analysis—Structural analysis was
done by digesting an aliquot of the isolated GAG with chondroitinase
ACII and another aliquot with chondroitinase ABC. Digestion with 40
milliunits/ml chondroitinase ABC was carried out in a buffer containing
5 mM calcium acetate, 1 mM phenylmethylsulfonyl fluoride, 0.36 mM
pepstatin, 0.1% Triton X-100, and 250 g/ml BSA in 100 mM Tris-HCl,
pH 7.2. Digestion with 40 milliunits/ml chondroitinase ACII occurred in
a buffer containing 100 mM sodium acetate, 0.1% Triton X-100, and 250
g/ml BSA in 100 mM Tris-HCl, pH 7.3. Digested products were analyzed
by Centricon 3 microconcentrators and gel permeation chromatography
as described (8). The percentage that is ACII-resistant reflects iduronic
acid content. Radiolabeled disaccharides were analyzed by HPLC using
a SAX column exactly as described (20).
Similarly, heparan sulfate can be characterized in terms of “maturi-
ty” by the degree to which its GlcN residues are N-sulfated. Heparan
sulfate GAGs were depolymerized with pH 1.5 nitrous acid for 10 min
at room temperature and quenched by the addition of 1.0 M Na2CO3
(21). Depolymerized samples were then reduced with NaBH4 (0.25 M
NaBH4 in 0.1 N NaOH at 50 °C for 30 min). Free [
35S]SO4
2 was quan-
tified by descending paper chromatography as reported previously (19).
Disaccharide analysis was done by SAX column chromatography as
described (22).
Determination of Specific Activity of [3H]Glucosamine Labeling
Pool—The specific activity of the [3H]GlcN radiolabeling pool in bone
cells from the age span under study was determined essentially as
described (23–25). Briefly, the large chondroitin sulfate PG was isolated
and digested with chondroitinase ABC (40 milliunits/ml). The resultant
unsaturated disaccharides separated by HPLC and the amount of
[35S]SO4
2 and [3H]GalN associated with each disaccharide were quan-
titated by chromatography on a Partisil PAC 10 column (26).
Determination of Structural Effects of Different Matrix Growth Sub-
strates—The entire surface of a 60-mm bacteriological Petri dish was
coated with 0.5 ml of protein solution of each examined Arg-Gly-Asp
(RGD)-containing protein solution in phosphate-buffered saline con-
taining 1 mM CaCl2. After a 16-h incubation at 4 °C, the fluid was
aspirated, and 0.5 ml of 60% methanol was added to each well (or the
entire dish was covered with a thin layer of methanol) followed by 2 h
of incubation at 4 °C. The methanol fixation was found to improve the
stability and durability of the protein-coated area (15, 28) without
significant changes of the biological activity of the substratum (as
evaluated by attachment properties). Methanol was then aspirated, and
FIG. 2. Normal dermatan sulfate proteoglycan maturity. The
iduronate content of BGN and DCN derived from normal donors was
analyzed. [3H]Iduronate levels were determined by differential diges-
tion with chondroitinase ABC and ACII as described under “Experi-
mental Procedures.” The resultant iduronate content was plotted as a
function of donor age (A). The amount of [3H]disaccharides released by
chondroitinase ACII digestion was determined by HPLC analysis and
plotted as a function of donor age (B). Analyses were done in triplicate,
and the error bars represent the means  S.D. IdoUA, iduronic acid;
DSPG, dermatan sulfate, PG.
FIG. 3. Normal syndecan-like proteoglycan maturity. The de-
gree of N-sulfation of heparan sulfate derived from normal osteoblasts
was determined as described under “Experimental Procedures.” The
degree of N-sulfation (A) and the extent of N-sulfated disaccharide
blocks (B) were plotted as a function of donor age. Analyses were done
in triplicate, and the error bars represent the means  S.D. HSPG,
heparan sulfate syndecan-like PG.
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the plates were washed for 30 min at 4 °C with washing buffer (50 mM
Tris-HCl, pH 7.8, 110 mM NaCl, 5 mM CaCl2, 0.1 mM phenylmethylsul-
fonyl fluoride, 1% BSA, and 0.01% sodium azide). This was followed by
washing three times with serum-free medium containing DMEM/Ham’s
F-12 (1:1) supplemented with 2 mM glutamine, 100 units/ml penicillin/
streptomycin, 0.5% ITS, and 50 g/ml ascorbate (serum-free
medium).
Cells in third passage from normal donors over the age of 60 years,
after reaching confluence, were released from culture dishes by trypsin-
EDTA treatment and, following sedimentation, were resuspended in
serum-free medium. Following a 30-min incubation at 37 °C, cells were
plated onto plastic precoated with RGD-containing proteins at a density
of 40,000 cells/cm2, and 36 h after plating, medium was aspirated and
replaced with serum-free medium containing 50 Ci/ml [35S]SO4
2. Af-
ter 12 h of labeling, media were collected, and cell layers were either
extracted using 4 M guanidinium HCl or dissolved in gel sample buffer
(GSB, consisting of 30% glycerol, 4% SDS, 2 M urea in 0.625 M Tris-HCl
buffer). Aliquots of both medium and cell layer fractions were subjected
to 3–15% bisacrylamide gradient gel electrophoresis and fluorography
(8). Borohydrate-treated specimens (-elimination) were analyzed by
HPLC.
In order to characterize the GAG chains and O-linked oligosaccha-
rides, medium fractions obtained from cells plated on RGD-containing
proteins and labeled with [6-3H]GlcN were separated on 3–15% gradi-
ent SDS-PAGE. By using an Erickman gel slicer, 1-cm wide gel lanes
were cut into 1-mm long slices and, after dissolving the gel slices in
H2O2 at 60 °C overnight, the amount of incorporated [
3H]GlcN
[3H]GalN was counted within each slice. A band containing the peak
corresponding to BGN and DCN was excised from the remaining part of
the gel, cut into small (2/2-mm) fragments, washed with water, and
lyophilized. Dried gel fragments were incubated with 0.3 M NaBH4 in
0.4 M NaOH for 24 h in order to cleave off GAG chains and O-linked
oligosaccharides (12). The reaction was stopped by bringing the pH to 1
with acetic acid for 1 h, and then samples were neutralized with 2 M
NaOH. The samples were lyophilized, resuspended in water, and sub-
jected to gel filtration analysis using the TSK-GEL HW 40(S) column
equilibrated with ammonium acetate buffer (0.5 M ammonium acetate,
10% methanol, pH 6.0). The samples (0.2–0.5 ml volume) were run at
the flow rate of 0.5 ml/min; 0.5-ml fractions were collected, and the
amount of radioisotope incorporated into every fraction was counted in
a scintillation counter.
RESULTS
Proteoglycan Distribution—In skin and cartilage, the distri-
bution and structure of PGs change with age (13, 29–36). To
test for such changes in osteoblasts, fingerprint profiles of the
four PGs produced by bone cells derived from normal and OI
donors were analyzed by steady-state radiolabeling and quan-
tifying label incorporation into specific PGs (Fig. 1). For osteo-
blasts derived from normal donors, the versican-like chon-
droitin sulfate PG (CSPG) was initially the major PG. With
increasing age, CSPG levels decreased, and other PGs in-
creased in abundance, although absolute levels were reduced
(Fig. 1, A–F). OI osteoblasts derived from patients of any age
FIG. 4. Normal O-linked oligosaccharide modifications. The ra-
tio of radiolabel incorporation into O-linked oligosaccharides to GAG
chains was determined as described under “Experimental Procedures”
(A). The specific activity of the metabolic precursor pool for the versican-
like PG was determined by following the ratio of [3H]GalN to [35S]SO4
2
in the unsaturated disaccharides produced by chondroitinase ABC di-
gestion (B). For both O-linked modifications and specific activity, the
values were plotted as a function of donor age; analyses were done in
triplicate, and the error bars represent means  S.D.
FIG. 5. OI proteoglycan structural analysis. [3H]GlcN- and
[35S]sulfate-labeled PGs were isolated, purified, and subjected to alka-
line -elimination with NaBH4 to cleave O-linked glycosidic-amino acid
linkages. Label incorporation into intact versican-like PG (A) or BGN
(B), GAG chains, and O-linked oligosaccharides was determined by
chromatography on a Toyopearl TSK HW 40(S) column. Representative
profiles derived from a fetal donor, a 3-year-old OI type III donor, and
a 4-year-old normal donor are shown. CSPG2, versican-like chondroitin
sulfate PG; NL, normal.
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exhibited a “fetal-like” PG fingerprint, with the CSPG staying
the major component at all ages. The absolute levels of all four
PGs were consistently low at all OI donor ages (Fig. 1, G–L) and
similar to the absolute levels observed in cells derived from
much older normal donors. Thus, OI-derived PGs exhibited a
fetal distribution pattern, but levels produced were similar to
those from aged normal donors. To distinguish whether the
observed alterations in OI bone cell extracellular matrix pro-
duction arose from a type I collagen mutation causing an arrest
of the cells in a fetal-like state or whether a consequence on the
mutation was a premature aging of the cells, the fine structure
of the PGs was investigated.
Normal Proteoglycan Structure—The iduronate content of
the dermatan sulfate containing PGs BGN and DCN derived
from 14 different normal donors was determined by radiolabel-
ing normal osteoblasts with [35S]SO4
2 and [3H]GlcN, isolating
the GAGs, and carrying out a differential digestion with chon-
droitinase ABC versus ACII. The amount of radiolabeled ma-
terial digested by ACII (which will not degrade iduronate-
containing oligosaccharides) was compared with the amount
digested by chondroitinase ABC (which degrades the GAG com-
pletely to disaccharides). The iduronate content was deter-
mined as ((ABC digested cpm  ACII digested cpm)/ABC di-
gested cpm}. A positive linear correlation between iduronate
content and donor age was observed. Iduronate content in-
creased 1.5-fold between fetal and 60 years of age (Fig. 2A). A
complementary measure of the maturity of dermatan sulfate
PGs was obtained by quantifying the levels of [3H]GlcN-labeled
disaccharides released from chondroitinase ACII treatment by
SAX column HPLC. An increase in iduronate content would be
reflected in fewer disaccharides being released (as chondroiti-
nase ACII does not cleave at iduronate moieties). The number
of [3H]disaccharides released by chondroitinase ACII treat-
ment decreased linearly with increasing donor age for chains
derived from normal donors (Fig. 2B).
Similarly, heparan sulfate can be characterized in terms of
“maturity” by the degree to which its GlcN residues were N-
sulfated. Sulfation of GlcN residues is a key enzymatic step
required before further enzymatic modifications, such as glu-
curonate epimerization and O-sulfation can occur (37). The
extent of N-sulfation can easily be assessed with [35S]GAGs by
low pH nitrous acid deaminative treatment that will cleave
heparan sulfate at GlcNSO3 residues, liberating free
[35S]SO4
2, disaccharides, tetrasaccharides, and larger oligo-
saccharides. The amount of free 35SO4
2 directly reflects the
extent of N-sulfation. This was done for all normal donor-
derived heparan sulfate chains. The results (Fig. 3A) indicated
that chains derived from normal donors exhibited an age-de-
pendent increase in extent of N-sulfation. The N-sulfation of
post-natal heparan sulfate increased over 3.5-fold until reach-
ing a plateau during the 4th decade of life. Analysis of the
[3H]GlcN-labeled disaccharides generated following nitrous
acid cleavage of N-sulfated disaccharide blocks by SAX column
HPLC demonstrated a parallel measure of heparan sulfate
maturity. Again, heparan sulfate chains derived from normal
cells showed an age-related pattern with increasing disaccha-
ride blocks with increasing age (Fig. 3B).
Normal Proteoglycan O-Linked Modifications—Previous
work (12) has shown that the degree of O-linked oligosaccha-
ride modification to the core proteins of bone PGs change sig-
nificantly in samples derived from either fetal or newborn
donors. A more extensive analysis of the influence of donor age
on core protein post-translational modifications was under-
taken. Radiolabeled CSPG and BGN derived from the osteo-
blast-like cells of 14 normal donors were isolated, and the
amount of label incorporation into O-linked oligosaccharides
and free GAG chains was analyzed by HPLC resolution follow-
ing alkaline borohydride treatment. The levels of 3H-labeled
O-linked oligosaccharides were expressed as the ratio of radio-
label incorporation into O-links versus radiolabel incorporation
into GAG chains. The degree of O-linked post-translational
modification decreased linearly with increasing age from fetal
to age 30 for both the CSPG and BGN (Fig. 4A). After age 30,
the ratio was constant.
Labeling Pool Specific Activity—When extracellular matrix
component stoichiometry was determined in vitro, the result-
ant levels of radiolabel incorporated into specific matrix com-
ponents is a function of the specific activity of the precursor
pool. The possibility exists that age-related alterations in PG
levels were caused by metabolic changes in the specific activity
of precursor pools (that may be a function of patient age, bone
cell metabolic state, etc.). The specific activity of precursor
pools involved in PG synthesis was analyzed by determining
the [3H]GlcN radiolabeling precursor pool activity that, be-
cause GlcN rapidly equilibrates with GalN, is the same as
[3H]GalN. This was tested by determining the ratio of
[3H]GalN to [35S]SO4
2 counts/min incorporation in the unsat-
urated disaccharides liberated from the CSPG by chondroiti-
nase ABC digestion. This PG has a GAG composition of almost
entirely chondroitin 4-sulfate (38). Thus, each unsaturated dis-
accharide produced by enzymatic digestion should possess one
[35S]SO4
2 per [3H]GalN residue. When the ratio of [3H]GalN to
[35S]SO4
2 counts/min in the unsaturated disaccharide was an-
FIG. 6. OI glycosaminoglycan size. The relative size of the liber-
ated free heparan sulfate (A) or dermatan sulfate (B) GAG chains
derived from OI donors was analyzed by chromatography on a 50 
1-cm ToyoPearl TSK HW 55(S) column. Representative profiles derived
from a fetal donor, a 4-year-old OI type III donor, and a 4-year-old
normal donor. NL, normal.
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alyzed, the ratio did not change significantly for normal sam-
ples (Fig. 4B).
OI Proteoglycan Structure—The observed age-related
changes in normal PG structure suggest that these post-trans-
lational modifications could be used to test whether OI donor-
derived osteoblasts exhibit a phenotype consistent with ad-
vanced aging or with an arrest in a fetal-like state. When the
component structure of isolated PGs derived from OI donors
was analyzed by size exclusion chromatography following
-elimination and borohydride reduction, distinct profiles were
evident. A representative profile is shown in Fig. 5, where the
levels of O-linked oligosaccharides from fetal, 4-year-old nor-
mal, and 4-year-old OI type III bone cell-derived samples of
purified versican-like PG and BGN were determined. By this
method of profiling, the GAG chains eluted in the void volume,
so no conclusion was made on chain size variation. However,
O-linked oligosaccharides were eluted in the included column
volume, and comparisons were made. The OI-derived osteo-
blast strains exhibited increased levels of O-linked oligosaccha-
rides similar to that seen in normal fetal-derived O-links. The
size of the GAG chains between normal and OI-derived PGs
was compared by HPLC analysis using a size exclusion chro-
matography column where the chains eluted in the included
volume (Fig. 6). Intact GAGs from all OI bone cultures were
similar in size as they co-eluted on gel permeation chromatog-
raphy, consistent with the observed absence of changes in
iduronate or N-sulfation content. Comparison of normal to
OI-derived GAG chains did not yield a significant difference in
the elution position. However, the polydispersity of the peaks
reflecting carbohydrate structural heterogeneity was consis-
tently greater in the normal donor-derived samples.
The GAG chains derived from OI donors were then analyzed
for extent of post-translational modifications. This was done by
analyzing the iduronate content in dermatan sulfate GAGs and
N-sulfation in heparan sulfate GAGs isolated from osteoblast-
like cells derived from 26 different OI donors. When the extent
of iduronate epimerization in dermatan sulfate chains from
BGN and DCN derived from OI osteoblasts was determined,
the percentage of iduronate remained relatively constant with
increasing donor age (Fig. 7A). In contrast to normal cells, the
number of disaccharides released from samples derived from
OI osteoblasts remained relatively constant at all ages (Fig.
7B). Similarly, heparan sulfate chains derived from OI cells
failed to express the normal age-dependent increase in N-
sulfation and N-sulfated disaccharide blocks (Fig. 7, C and D).
OI donor-derived PG core protein O-linked modifications
were profiled by comparing the ratio of O-linked oligosaccha-
rides to GAGs (Fig. 8A). Milder OI forms (types I and IV)
exhibited a ratio that was similar to the normal age-matched
pattern. PGs derived from OI patients with a more severe
phenotype (OI types II and III) exhibited higher O-linked gly-
cosylation. To rule out the possibility that the observed differ-
ences in OI PG levels and structure were due to changes in the
specific activity of the metabolic precursor pool, the specific
activity of the [3H]GalN and [35S]SO4
2 precursor pools was
investigated in OI-derived samples. The ratio of [3H]GalN to
[35S]SO4
2 in the unsaturated chondroitin 4-sulfate disaccha-
ride did not change significantly for all OI samples analyzed
(Fig. 8B). The major differences between normal and OI-de-
rived PGs did not arise from differences in the specific activity
of the precursor pool. All PGs derived from OI donors failed to
parallel the age-related increase in dermatan sulfate iduronate
content or heparan sulfate N-sulfation seen in PGs derived
from normal donors. The structural pattern observed in OI-
derived PGs was similar to the structural features seen in
normal PGs derived from fetal donors. By using the post-trans-
lational modifications of PGs as surrogate biochemical markers
of physiologic age suggests that, in the presence of a mutation
in type I collagen, osteoblast cells exhibit a phenotype arrested
in a fetal-like state.
Extracellular Matrix Effects on Post-translational Modifica-
tions—The potential biological significance of these observa-
tions was investigated by testing whether the altered PG post-
translational modification seen in cells from OI donors might
be associated with the altered extracellular matrix composi-
tion, i.e. whether common constituents of extracellular matrix
that are known to interact with cells via specific receptors are
capable of inducing the fetal-like post-translational modifica-
FIG. 7. OI proteoglycan maturity.
The maturity of BGN and DCN derived
from OI donors was analyzed. [3H]Idur-
onate levels (A) as well as the amount of
[3H]disaccharides released by chondroiti-
nase ACII digestion (B) were determined
and plotted as a function of donor age.
The degree of N-sulfation of heparan sul-
fate derived from OI osteoblasts was de-
termined. The degree of N-sulfation (C)
and the extent of N-sulfated disaccharide
blocks (D) were plotted as a function of
donor age. Analyses were done in tripli-
cate, and the error bars indicate means 
S.D. The shaded area represents the
range of the data observed for normal do-
nor-derived PGs. IdoUA, iduronic acid;
DSPG, dermatan sulfate PG; DS, derma-
tan sulfate; HSPG, heparan sulfate syn-
decan-like PG; HS, heparan sulfate.
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tions of PGs in normal adult-derived osteoblasts. The extent of
post-translational modifications to PGs can be grossly com-
pared by migration position on SDS-PAGE. Adult-derived bone
cells were plated on different matrix glycoproteins, and the
cells were radiolabeled to follow PG levels and structure. Cells
exposed to thrombospondin secreted PGs that migrate on the
gel as higher Mr species than those secreted by cells plated on
fibronectin, vitronectin, collagen, osteopontin, and bone sialo-
protein (Fig. 9). This pattern was reproducible and occurred in
all experiments and over extended time courses (data not
shown).
A typical profile of alkaline borohydride treatment of a rep-
resentative BGN sample purified as described from cells at-
tached to collagen and thrombospondin is shown in Fig. 10A.
This type of analysis made it possible to quantitate the relative
incorporation of radioisotope into GAG chains and oligosaccha-
rides. The high Mr BGN (secreted by cells plated onto throm-
bospondin) showed isotope incorporation mostly into O-linked
oligosaccharides and to a lesser extent into GAG chains,
whereas in the lower Mr BGN (secreted by cells grown on other
RGD-containing matrix components), the major peak appears
to be composed of GAG chains. TGF- is known to co-purify
with thrombospondin (39), and TGF- has been implicated in
the regulation of small PG metabolism (40–42). The effect of
TGF-1 on PG post-translational modification was investi-
gated by adding exogenous TGF-1 prior to radiolabeling of the
cells. However, BGN secreted by cells in the presence of
TGF-1 exhibited a profile showing greater radiolabel incorpo-
ration into GAG chains with little effect on O-linked oligosac-
charides (Fig. 10A, inset).
The ratio of O-linked oligosaccharides to GAGs was exam-
ined as a function of OI type and compared with normal adult
and fetal donor ratios. When the ratios were averaged within a
given OI type, increasing disease severity was associated with
increasing O-linked oligosaccharide modifications (Fig. 10B).
Between the mildest OI type and most severe type, the ratio
increased 1.6-fold. The changes in the ratio paralleled the
changes in total thrombospondin levels produced by these same
cells. The ratio of O-linked oligosaccharides to GAGs was next
determined in osteoblasts derived from an adult donor (65
years of age) whose cells were cultured and radiolabeled on
either a type I collagen substrate, a collagen  TGF-1, or a
thrombospondin substrate. The addition of TGF-1 to a colla-
gen substrate decreased the ratio, consistent with an effect on
radiolabel incorporation into the GAG. The presence of throm-
bospondin led to a 2-fold increase in the ratio of O-linked
oligosaccharides to GAGs (Fig. 10C).
DISCUSSION
PG synthesis begins in the rough endoplasmic reticulum
where N-linked oligosaccharides are added co-translationally
to the nascent core protein (43). Once in the Golgi, high man-
nose N-linked oligosaccharides are modified, and O-linked oli-
gosaccharides are added. GAG chain addition begins in the
lumen of the endoplasmic reticulum and proceeds as the core
FIG. 8. OI O-linked oligosaccharide modifications and specific
activity. The ratio of radiolabel incorporation into O-linked oligosac-
charides to GAG chains was determined for BGN derived from OI
donors (A). The specific activity of the metabolic precursor pool for the
versican-like PG was determined in OI donor cells by following the ratio
of [3H]GalN to [35S]SO4
2 in the unsaturated disaccharides produced by
chondroitinase ABC digestion (B). For both O-linked modifications and
specific activity, analyses were done in triplicate, and the values were
plotted as a function of donor age. The shaded area represents the range
of the data observed for normal donor-derived PGs.
FIG. 9. Matrix RGD-protein effects on proteoglycan size. Osteoblasts derived from a 10-year-old type II OI donor and an age-matched
normal were grown on tissue culture plastic, radiolabeled with [35S]SO4
2, and the relative migration positions of the PGs determined by 3–15%
SDS-PAGE analysis and fluorography (A). The lanes were loaded with molecular weight standards (lane 1), samples from the OI-derived medium
pool (lane 2), OI-derived cell layer pool (lane 3), normal medium pool (lane 4), and normal cell layer pool (lane 5). Cells from a normal adult donor
(age 65 years) were plated on either serum-free conditioned medium (lane 1), thrombospondin (lane 2), fibronectin (lane 3), vitronectin (lane 4),
collagen type I (lane 5), osteopontin (lane 6), or bone sialoprotein (lane 7). The relative size of the PGs was profiled by 3–15% SDS-PAGE analysis
(B). CSPG2, versican-like PG; HSPG, syndecan-like PG. Arrows mark the relative migration positions of the PGs.
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protein traverses the intracellular secretory pathway (44).
These GAG chains define the class of the PG by a general
repeating disaccharide backbone. For heparin, heparan sulfate,
chondroitin sulfate, and dermatan sulfate PGs, the backbone
consists of (hexuronic acid-N-acetylhexosamine)n which can
have sulfate ester substituents on either the uronic acid or
hexosamine or both (7). Dermatan sulfate is distinguished from
chondroitin sulfate by the epimerization of glucuronate resi-
dues to iduronate and by 2-O-sulfation of those iduronate res-
idues. Heparin is distinguished from heparan sulfate by pos-
sessing a higher degree of N-sulfated glucosamine residues and
more O-sulfation (of both the uronic acid and glucosamine
residues). Dermatan sulfate containing PGs are defined as
mature based on their iduronate content, whereas heparan
sulfate containing PGs are defined by their extent on N-sulfa-
tion of glucosamine residues (37, 45).
The distribution and structure of PGs has been found to
change with age in a number of different tissues/organs. The
ratio of keratan sulfate to chondroitin sulfate chains was found
to increase with increasing age in lumbar intervertebral discs
(29, 30). In intervertebral discs and hyaline cartilage, the size
range of the PGs exhibited greater polydispersity with increas-
ing age (33–35). The degree of N-sulfation of cell-associated
heparan sulfate increased with age in gingival fibroblasts (31).
In skin fibroblasts, the levels of versican were found to decrease
and DCN increased with age (36). Older skin also exhibited a
greater polydispersity in size. The current study was under-
taken to determine whether similar age-related changes oc-
curred in normal bone cell-derived PGs. Changes in the extent
of post-translational modifications to both heparan and derma-
tan sulfate chains of bone PGs were observed in the current
study. The correlation of donor age with changes in normal
bone cell PG fine structure suggested that these specific alter-
ations might be used as surrogate markers of a physiologic age
of the tissue/cells synthesizing the PG. The utility of the PG
fine structures as such markers was investigated by studying
PGs derived from OI donors.
Previous work has shown that the stoichiometry of extracel-
lular matrix components made by OI bone cells was different
from that of age-matched controls (9, 17). In addition to type I
collagen, the synthesis of the four bone PGs was reduced in OI
cells (9). The levels of other matrix components, hyaluronan as
well as fibronectin and thrombospondin, were elevated in the
extracellular matrix pool compared with age-matched controls
(17). The proliferative capacity and growth rate of OI cells were
reduced relative to normal cells (11). Finally, the observed
changes in OI bone matrix stoichiometry persisted in long term
culture (10). The reduced levels of matrix expression in osteo-
blast-like cells derived from young donors with OI (compared
with normal age-matched controls) were within the normal
range seen for cells derived from healthy donors over the age of
60 years. One possible interpretation of the observed alter-
ations in extracellular matrix stoichiometry was that OI osteo-
blasts fail to parallel the normal bone cell developmental ex-
pression pattern because they exhibit a prematurely aged
expression pattern. If this were the case then biochemical
markers of this aged state should be identifiable.
By using bone PG post-translational modification structure
as surrogate markers for physiologic age, cells derived from OI
donors are fetal-like in terms of PG distribution, GAG matu-
rity, and O-linked modifications. The pattern of expression and
fine structure of the PGs were consistent with OI-derived os-
teoblasts failing to follow a developmental differentiation pat-
tern. This failure in differentiation may contribute to the
pathophysiological consequences observed in the OI phenotype.
Although the absolute levels are equivalent to cells derived
from aged normal donors, both the distribution among the four
PGs and the degree of O-linked oligosaccharide modifications
were found to be similar to the fetal-like pattern. Thus the
hypothesis that the reduction in extracellular matrix produc-
tion as well as reduced proliferative rates of OI-derived osteo-
blast-like cells was a manifestation of advanced aging can be
excluded. The observed lack of change in OI cell GAG modifi-
cation (epimerization and sulfation pattern) was consistent
with a failure of cells to progress from the fetal state of expres-
sion patterns. There was no clear correlation between severity
of disease (OI type) and the type of PG fine structure. The
observation of PGs possessing O-linked oligosaccharide struc-
tures of a fetal-like nature, which did not change with increas-
ing age of the OI donor, point to a fundamental error in the
normal differentiation pathway of osteoblasts as a consequence
of a mutation in type I collagen.
When normal adult cells were cultured on thrombospondin
(but not fibronectin, vitronectin, type I collagen, osteopontin, or
bone sialoprotein) the post-translational pattern of small ma-
FIG. 10. Matrix RGD-protein effect on proteoglycan post-
translational modifications. The products of alkaline borohydride
treatment of BGN obtained from normal adult cells plated on collagen
(open square) or thrombospondin (closed triangle) and labeled with
[3H]GlcN were profiled by TSK-GEL HW 40(S) column HPLC (A). A
representative profile of 3H-labeled GAGs and O-linked oligosaccha-
rides derived from BGN obtained from the same cells grown on collagen
treated with TGF-1 is shown in the inset. The ratio of O-linked oligo-
saccharides to GAGs was averaged among all adult normal donors (n 
12), each OI type (n  6 for type I, n  2 for type II, n  6 for type II,
and n  8 for type IV), and among normal fetal donors (n  2) for
comparison (B). For comparison, the levels of thrombospondin (cross-
hatched bars) were averaged by phenotype from previously published
values (17). Error bars represent means  S.D. The ratio of O-linked
oligosaccharides to GAGs for BGN derived from normal adult cells
grown and radiolabeled on collagen, collagen  TGF-1, or throm-
bospondin was determined (C).
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trix PGs closely resembles the pattern characteristic for osteo-
blastic cells obtained from OI donors as well as normal fetal
donors, even though cells used for these set of experiments
were obtained from a 65-year-old donor. Interestingly, both
fetal bone cell cultures and cells derived from donors with OI
synthesize and secrete significantly higher levels of throm-
bospondin than cultures obtained from normal adult donors
(17). It may be that the over-glycosylation of the oligosaccha-
rides observed for OI and fetal cells is a consequence of an
“autocrine” effect of thrombospondin, synthesized in higher
amounts by these cells. It is also possible that elevated throm-
bospondin and altered PG post-translational modifications re-
flect an underlying altered phenotypic expression pattern.
The major source of thrombospondin is the -granules of
platelets (46), from which it is released following platelet acti-
vation and degranulation. This mechanism is one of the first
steps in the process of wound healing. It is possible that throm-
bospondin, apart from its involvement in promoting cell attach-
ment via several different mechanisms described (47), also
influences cell metabolism to make it more effective in the task
of rebuilding damaged matrix. Thus, it is conceivable that
under certain conditions (e.g. insufficient collagen and matrix
production in OI as well as increased fractures) osteoblastic
cells exist in a milieu that is essentially a damaged matrix, and
part of the programmed response is expression of an “elevated
thrombospondin/altered post-translational structure” pheno-
type with respect to their matrix metabolic activity.
The addition of TGF-1 to normal adult-derived bone cells
did not produce the altered O-linked oligosaccharides associ-
ated with OI. OI bone cells do not exhibit a TGF--dependent
increase in collagen synthesis and alkaline phosphatase activ-
ity seen with normal bone cells (48). OI osteoblasts had a
greater reduction in TGF- receptor I–III number than age-
matched controls, and receptor affinity was unchanged,
whereas ligand-induced modulation of receptor number was
found to be impaired in the OI cells (49). Thus, the association
of elevated thrombospondin levels with altered post-transla-
tional modifications in OI osteoblasts is unlikely to involve
TGF-.
Currently, over 250 distinct type I collagen mutations have
been identified in OI patients, with point mutations resulting
in substitutions for glycine residues being the most common
(50, 51). Although there are a large number (50) of exons in
COL1A1 and COL1A2 genes, single exon deletions are a rare
finding (52). Some mutations lead to the functional loss of the
affected allele, which has been suggested to cause mild (type I)
forms of OI (53). Mutations in the collagen genes of the severely
affected patients are thought to lead both to a reduced type I
collagen synthesis, secretion, and deposition of structurally
abnormal collagen molecules into the matrix (39, 54, 55). His-
tomorphometric studies of human OI types III and IV bone
have suggested that OI is associated with a high bone turnover
rate (56, 57). For adult OI type IA and perhaps in children with
mild disease, the turnover rate may not be as high (27, 58). The
increased turnover is believed to arise from increased oste-
oclastic activity in the presence of inadequate matrix produc-
tion by osteoblasts.
Based upon our in vitro observations of the effects of type I
collagen mutations on osteoblast proliferation, extracellular
matrix component expression, and PG fine structure, it is ap-
parent that the mutations that give rise to OI cause pleiotropic
effects far beyond the production of a structurally aberrant
type I collagen molecule. We hypothesize that although the
genotype for most cases of human OI is caused by mutations in
type I collagen, the phenotype may be defined by an altered
bone matrix stoichiometry and concomitant altered osteoblast
differentiation state, i.e. the pathophysiological consequences
of mutations in OI arise not solely from structural aberrations
in type I collagen but also from alterations in osteoblastic
differentiation. Altered osteoblastic differentiation may arise
from altered extracellular matrix feedback into cellular
metabolism.
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